Patents Examined by Celia Chang
  • Patent number: 9808006
    Abstract: A compound of formula (I) wherein A, p, R1, R3, R4, R5, R6, m, R7, n and R8 are as defined in claim 1. Furthermore, the present invention relates to intermediates used to prepare compounds of formula (I), to methods of using them to combat and control insect, acarine, nematode and mollusc pests and to insecticidal, acaricidal, nematicidal and molluscicidal compositions comprising them.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: November 7, 2017
    Assignee: Syngenta Participations AG
    Inventors: Thomas Pitterna, Jerome Yves Cassayre, Camilla Corsi, Peter Maienfisch
  • Patent number: 9790423
    Abstract: The present invention relates to cyanated naphthalenebenzimidazole compounds of the formula (I) and mixtures thereof, in which R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are each independently hydrogen, cyano or aryl which is unsubstituted or has one or more identical or different substituents RAr, where RAr is as defined in the claims and in the description, with the proviso that the compounds of the formula I comprise at least one cyano group. The invention further relates to color converters comprising at least one polymer as a matrix material and at least one cyanated naphthalenebenzimidazole compound or mixtures thereof as a fluorescent dye, to the use of the color converters and to lighting devices comprising at least one LED and at least one color converter.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: October 17, 2017
    Inventors: Martin Könemann, Gabriele Mattern, Gerhard Wagenblast, Sorin Ivanovici, Robert Send
  • Patent number: 9777018
    Abstract: The present invention relates to novel compounds of formula (A) and (B) as modulators of GPR-119, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of GPR-119 mediated diseases or disorders with them.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: October 3, 2017
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Dhanapalan Nagarathnam, Swaroop K. Vakkalanka, Srikant Viswanadha, Gayatri S. Merikapudi
  • Patent number: 9776965
    Abstract: The N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is 1 or 2; L represents a C1-3alkyl linker optionally substituted with one or two substituents selected from C1-4alkyl, C1-3alkyloxy-C1-4alkyl-, hydroxy-C1-4alkyl, hydroxy, C1-3alkyloxy- or phenyl-C1-4alkyl; M represents a direct bond or a C1-3alkyl linker optionally substituted with one or two substituents selected from hydroxy, C1-4alkyl or C1-4alkyloxy; R1 and R2 each independently represent hydrogen, halo, cyano, hydroxy, C1-4alkyl optionally substituted with halo, C1-4alkyloxy- optionally substituted with one or where possible two or three substituents selected from hydroxy, Ar1 and halo; or R1 and R2 taken together with the phenyl ring to which they are attached form naphtyl or 1,3-benzodioxolyl, wherein said naphtyl or 1,3-benzodioxolyl are optionally substituted with halo; R3 represents hydrogen, halo, C1-4alkyl, C1-4alkyloxy-, cyano or hydroxy; R4 represents hydrogen, halo,
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: October 3, 2017
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Libuse Jaroskova, Joannes Theodorus Maria Linders, Christophe Francis Robert Nestor Buyck, Louis Jozef Elisabeth Van Der Veken, Vladimir Dimtchev Dimitrov, Theo Teofanov Nikiforov
  • Patent number: 9771326
    Abstract: Compounds of formula (I), and pharmaceutically acceptable salts thereof, can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: September 26, 2017
    Assignee: BIOGEN MA INC.
    Inventors: Hairuo Peng, Zhili Xin, Lihong Sun, Timothy Chan, Gnanasambandam Kumaravel, Arthur G. Taveras
  • Patent number: 9771348
    Abstract: The present invention relates to a method for preparing N-[[1-{3-(1,2,3-triazol-1-yl)propyl}piperidin-4-yl]methyl]-4-amino-5-chloro-2-methoxybenzamide, which is a novel benzamide derivative as a 5-HT4 receptor agonist, or a pharmaceutically acceptable salt thereof; to a novel intermediate capable of being used in the preparation of the compounds; and to a method for preparing the same. The preparation methods of the present invention can be useful for mass production since a low-priced reagent and intermediate are used and the number of reaction processes is decreased, thereby saving preparation costs and improving the yield.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: September 26, 2017
    Assignee: DONG-A ST CO., LTD
    Inventors: Woo Young Kwak, Kyung Seok Lee, Ullapu Punna Reddy, Soon Kyu Jung, Tae Sun Park, Joong In Lim
  • Patent number: 9771374
    Abstract: Provided herein are compounds of the formulas (I) and (II): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: September 26, 2017
    Assignee: INNOV17 LLC
    Inventors: Anderson Gaweco, Jefferson Tilley, James Blinn
  • Patent number: 9771327
    Abstract: The invention relates to a compound of Formula I and methods of treating CFTR (cystic fibrosis transmembrane conductance regulator) mediated diseases, in particular cystic fibrosis, comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof:
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: September 26, 2017
    Assignee: FLATLEY DISCOVERY LAB, LLC
    Inventors: Michael P. Zawistoski, Yevgen Barsukov, Bridget M. Cole, Richard A. Nugent
  • Patent number: 9765027
    Abstract: The invention provides compounds that bind with high affinities to the ?-, ?- and ?-opioid receptors and ?2-adrenoreceptor. In addition to providing these compounds with novel pharmacological binding properties, the invention also describes detailed novel methods for the preparation of representative compounds and a scheme for the synthesis of related compounds that bind to the opioid receptors and/or ?2-adrenoreceptor.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: September 19, 2017
    Assignee: Arizona Board of Regents on behalf of the University of Arizona
    Inventors: Ruben S. Vardanyan, Victor J. Hruby
  • Patent number: 9751871
    Abstract: Bis(difluoromethyl)pyrazole derivatives of the formula (I) in which the symbols R1, X and G are each as defined in the description, and agrochemically active salts, metal complexes and N-oxides thereof, and use thereof for controlling phytopathogenic harmful fungi, and also processes for preparing compounds of the formula (I).
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: September 5, 2017
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Pierre Cristau, Sebastian Hoffmann, Joachim Kluth, Tomoki Tsuchiya, Pierre Wasnaire, Jurgen Benting, Daniela Portz, Ulrike Wachendorff-Neumann, Stefan Hillebrand
  • Patent number: 9751859
    Abstract: The present invention relates a new process to synthesize 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine (AL3818). A stable crystalline form of Al3818 has been prepared. Salts and their crystalline forms of AL3818 have been also prepared. Anti-cancer and optometric activities of AL3818 and its salts have been further tested. New process has been outlined in Scheme I.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: September 5, 2017
    Assignee: Advenchen Pharmaceuticals, LLC
    Inventors: Guoqing Paul Chen, Changren Yan
  • Patent number: 9750733
    Abstract: Described are novel salts of the compound (3R,4R,5S)-5-(difluoromethyl) piperidine-3,4-diol, as well as methods of using the same for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease and/or Parkinson's disease.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: September 5, 2017
    Assignee: AMICUS THERAPEUTICS, INC.
    Inventors: Robert Boyd, Philip J. Rybczynski, Kamlesh Sheth
  • Patent number: 9751836
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: September 5, 2017
    Assignee: HELSINN HEALTHCARE SA
    Inventors: Silvina Garcia Rubio, Claudio Pietra, Claudio Giuliano, Zhigang Li
  • Patent number: 9718779
    Abstract: The present invention provides a novel intermediate as well as novel polymorphs of 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide compound represented by the following structural formula-1 and processes for their preparation.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: August 1, 2017
    Assignee: MSN Laboratories Limited
    Inventors: Srinivasan Thirumalai Rajan, Sajja Eswaraiah, Mummadi Venkatesh
  • Patent number: 9718776
    Abstract: A benzilic acid ester compound represented by the following formula (I) or a salt thereof, wherein R represents optionally substituted fluorinated lower alkyl, is disclosed.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: August 1, 2017
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Masato Nanri, Kazuharu Noguchi, Fukumitsu Sakakibara, Shinichi Aoki
  • Patent number: 9718813
    Abstract: The present invention is directed to imidazolin-5-one derivatives, pharmaceutical compositions containing them, and their use as FASN inhibitors, in for example, the treatment of cancer, obesity related disorders, and liver related disorders. Such compounds are represented by formula (I) as follows: wherein R1, R2, R3, R4, R5, m, n, and are defined herein.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: August 1, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Peter J Connolly, Tianbao Lu
  • Patent number: 9694002
    Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: July 4, 2017
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Jean-Christophe Andrez, Paul Robert Bichler, Chien-An Chen, Sultan Chowdhury, Shannon Marie Decker, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Jun Li, Zhiguo Liu, Daniel F. Ortwine, Brian Safina, Daniel Sutherlin, Tao Sheng, Shaoyi Sun, Andrew D. White, Michael Scott Wilson, Alla Yurevna Zenova, Jiuxiang Zhu
  • Patent number: 9688678
    Abstract: The present invention relates to novel substituted oxindole derivatives of the formula I wherein A is a ring selected from phenyl and 6-membered hetaryl containing 1 or 2 nitrogen atoms as ring members, where ring A carries one substituent R6 and optionally one substituent R7; B is a ring selected from phenyl and a monocyclic or bicyclic heteroaromatic ring containing 1, 2 or 3 heteroatoms selected from O, N and S as ring members, where ring B may carry 1, 2 or 3 substituents R8; X1, X2, X3 and X4, independently of each other, are selected from —CH2—, —O—, —S(O)c—, —NH—, —C(O)—, —CH2CH2—, —CH2O—, —OCH2—, —S(O)cCH2—, —CH2S(O)c—, CH2NH—, —NHCH2—, —CH2C(O)— and C(O)CH2—; X5 is NH, CH2 or O; and wherein c, R1, R2, (R3)a, (R4)b, R5, R6, R7, and R8 are as defined in the claims. The present invention also relates to pharmaceutical compositions comprising the novel substituted oxindole derivatives of the formula I, and to their use for the treatment of vasopressin-related disorders.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: June 27, 2017
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Hervé Geneste, Wilfried Hornberger, Katja Jantos, Andreas Kling, Marcel Van Gaalen
  • Patent number: 9688693
    Abstract: A NK1 antagonist having the formula (I), wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: June 27, 2017
    Assignee: OPKO Health, Inc.
    Inventors: Sunil Paliwal, Gregory A. Reichard, Cheng Wang, Dong Xiao, Hon-Chung Tsui, Neng-Yang Shih, Juan D. Arredondo, Michelle Laci Wrobleski, Anandan Palani
  • Patent number: 9688632
    Abstract: A method for manufacturing amidomagnesium halogenides and admixtures thereof with alkali metal salts in aparotic, organic solvents, compounds obtained according to the method and use thereof in synthesis chemistry, for example for deprotonizing enolizable systems, functionalized aromatics and heteroaromatics.
    Type: Grant
    Filed: May 18, 2009
    Date of Patent: June 27, 2017
    Inventors: Alexander Murso, Christopher Kurth, Peter Rittmeyer